Brief: Tscan Therapeutics Announces First Patient Dosed In Phase 1 Umbrella Clinical Trial Evaluating Tsc-100 And Tsc-101 For The Treatment Of Hematologic Malignancies
14/03/2023 11:14
March 14 (Reuters) - TScan Therapeutics Inc TCRX.O :
* TSCAN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE
1
UMBRELLA CLINICAL TRIAL EVALUATING TSC-100 AND TSC-101 FOR THE
TREATMENT OF HEMATOLOGIC MALIGNANCIES
Source text for Eikon: ID:nGNX2v5XyB
Further company coverage: TCRX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing